nach oben

Erschienen in:

21.09.2023 | Original Article

Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 × 10⁹/L

verfasst von: Aoli Zhang, Lipeng Liu, Suyu Zong, Lixian Chang, Xiaojuan Chen, Wenyu Yang, Ye Guo, Li Zhang, Yao Zou, Yumei Chen, Yingchi Zhang, Min Ruan, Xiaofan Zhu

Erschienen in: International Journal of Hematology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute myeloid leukemia (AML) and hyperleukocytosis have an unfavorable prognosis, but the impact of hyperleukocytosis on the prognosis of pediatric AML remains uncertain. We investigated the clinical characteristics and prognosis of pediatric AML with hyperleukocytosis, defined as WBC ≥ 50 × 10⁹/L.

Methods

A total of 132 patients with newly diagnosed childhood AML with hyperleukocytosis were consecutively enrolled at our center from September 2009 to August 2021 to investigate prognostic factors and clinical outcomes.

Results

Hyperleukocytosis occurred in 27.4% of AML patients. Pediatric patients with hyperleukocytosis had similar CR and OS rates to those without hyperleukocytosis, but had a lower EFS rate. In our study, rates of CR1, mortality, relapsed/refractory disease, and HSCT were comparable between AML patients with WBC counts of 50–100 × 10⁹/L and ≥ 100 × 10⁹/L. AML patients with a WBC count of 50–100 × 10⁹/L had a similar 5-year OS rate to patients with a WBC count ≥ 100 × 10⁹/L (74.6% vs. 75.4%, P = 0.921). Among all patients with hyperleukocytosis, the FAB M5 subtype was associated with significantly inferior survival, and the prognosis of CBF-AML was good.

Conclusions

Pediatric AML patients with hyperleukocytosis have the similar prognosis regardless of whether their WBC count is 50–100 × 10⁹/L or ≥ 100 × 10⁹/L.

Nur mit Berechtigung zugänglich

Hall GW. Childhood myeloid leukaemias. Best Pract Res Clin Haematol. 2001;14:573–91.CrossRefPubMed

Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017;19:1–10.CrossRefPubMed

Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949–62.CrossRefPubMedPubMedCentral

Faulk K, Gore L, Cooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Paediatr Drugs. 2014;16:213–27.CrossRefPubMed

Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159:259–76.CrossRefPubMedPubMedCentral

Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987;5:1364–72.CrossRefPubMed

Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47:1245–52.CrossRefPubMed

Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–52.CrossRefPubMed

Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2012;97:1770–3.CrossRefPubMedPubMedCentral

10.

Xue Y, Chen J, Gao S, Zhai X, Wang N, Gao J, et al. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. Sci Rep. 2021;11:9656.CrossRefPubMedPubMedCentral

11.

Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24.CrossRefPubMed

12.

Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.CrossRefPubMedPubMedCentral

13.

Oliveira LC, Romano LG, Prado-Junior BP, Covas DT, Rego EM, De Santis GC. Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil. Med Oncol. 2010;27:1254–9.CrossRefPubMed

14.

Tien FM, Hou HA, Tsai CH, Tang JL, Chen CY, Kuo YY, et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. Eur J Haematol. 2018;101:86–94.CrossRefPubMed

15.

Canaani J, Labopin M, Socie G, Nihtinen A, Huynh A, Cornelissen J, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017;92:653–9.CrossRefPubMed

16.

Kittivisuit S, Jongthitinon N, Sripornsawan P, Songthawee N, Chavananon S, Limratchapong C, et al. Hyperleukocytosis in childhood acute leukemia: early complications and survival outcomes. Cancers (Basel). 2023;15:3072. https://doi.org/10.3390/cancers15123072CrossRefPubMedPubMedCentral

17.

Xu LH, Wang JW, Wang Y, Yang FY. Hyperleukocytosis predicts inferior clinical outcome in pediatric acute myeloid leukemia. Hematology. 2020;25:507–14.CrossRefPubMed

18.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.CrossRefPubMed

19.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed

20.

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.CrossRefPubMed

21.

Liu LP, Zhang AL, Ruan M, Chang LX, Liu F, Chen X, et al. Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. Cancer Med. 2020;9:3647–55.CrossRefPubMedPubMedCentral

22.

Zhang A, Liu L, Zong S, Chen X, Liu C, Chang L, et al. Pediatric non-Down’s syndrome acute megakaryoblastic leukemia patients in China: a single center’s real-world analysis. Front Oncol. 2022;12: 940725.CrossRefPubMedPubMedCentral

23.

Inaba H, Fan Y, Pounds S, Geiger TL, Rubnitz JE, Ribeiro RC, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008;113:522–9.CrossRefPubMed

24.

Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017;4:e202–17.CrossRefPubMedPubMedCentral

25.

Løhmann DJ, Abrahamsson J, Ha SY, Jónsson ÓG, Koskenvuo M, Lausen B, et al. Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica. 2016;101:1359–67.CrossRefPubMedPubMedCentral

26.

DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136:1023–32.CrossRefPubMedPubMedCentral

27.

Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2012;12:405–13.CrossRefPubMed

28.

Spring J, Munshi L. Hematology emergencies in adults with critical illness: malignant hematology. Chest. 2022;162:120–31.CrossRefPubMed

29.

Odom LF, Lampkin BC, Tannous R, Buckley JD, Hammond GD. Acute monoblastic leukemia: a unique subtype—a review from the Childrens Cancer Study Group. Leuk Res. 1990;14:1–10.CrossRefPubMed

30.

Tobelem G, Jacquillat C, Chastang C, Auclerc MF, Lechevallier T, Weil M, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood. 1980;55:71–6.CrossRefPubMed

31.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.CrossRefPubMed

32.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451–9.CrossRefPubMedPubMedCentral

33.

Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741–50.CrossRefPubMed

34.

Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group. Blood. 2021;138:1137–47.CrossRefPubMedPubMedCentral

Titel: Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 × 109/L
verfasst von: Aoli Zhang
Lipeng Liu
Suyu Zong
Lixian Chang
Xiaojuan Chen
Wenyu Yang
Ye Guo
Li Zhang
Yao Zou
Yumei Chen
Yingchi Zhang
Min Ruan
Xiaofan Zhu
Publikationsdatum: 21.09.2023
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Hematology / Ausgabe 6/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-023-03665-0

Springer Medizin

Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 × 10⁹/L